drugset / Trial / NCT04690387
Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection
Phase 1
Completed
27 enrolled
Aivita Biomedical, Inc.
Indonesia Ministry of Health · collabNational Institute of Health Research and Development, Ministry of Health Republic of Indonesia · collabPT AIVITA Biomedika Indonesia · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This is an adaptive Phase I trial of a vaccine consisting of autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein, with or without GM-CSF, to prevent COVID-19 in adults.
Timeline
- Start
- 2020-12-07
- Primary completion
- 2021-01-13
- Completion
- 2021-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AV-COVID-19 | Vaccine | 0.1 ug | Subcutaneous |
| Subject | AV-COVID-19 | Vaccine | 0.33 ug | Subcutaneous |
| Subject | AV-COVID-19 | Vaccine | 1 ug | Subcutaneous |